Perfuze Announces Appointment of New Chair of the Board
Benzinga Perfuze, a medical device company developing next-generation "super-bore" catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami as the new Chair of the Board. This appointment reflects Perfuze's commitment to bring devices to market that have the potential to transform the treatment of acute ischemic stroke. Hooman brings a wealth of experience and expertise to Perfuze, making him an invaluable addition to the company's leadership team. With an impressive track record in the medical device industry, Hooman has held prominent leadership positions within Medtronic and GE Healthcare, driving innovation, growth, and profitability.
As the new Chair of the Board, Hooman will play a pivotal role in guiding Perfuze's strategic direction and spearheading the company's mission to transform the treatment landscape for acute ischemic stroke. His previous Board experience and strategic insights will be instrumental in supporting the advance of Perfuze's groundbreaking technologies and therapies, ultimately improving patient outcomes. "I am honored to join Perfuze as the Chair of the Board," said Hooman. "Perfuze's commitment to developing innovative solutions for stroke aligns perfectly with my enthusiasm for advancing medical technologies that have the potential to significantly impact patients' lives. I am joining at an exciting time in the company's development, as we move towards enrolling our first patient in our upcoming pivotal US IDE clinical study. I look forward to collaborating closely with the talented team at Perfuze to achieve our shared vision."
